Arne Scheu
Co-Founder & Chief Executive Officer Valink Therapeutics
Arne is Co-Founder and CEO of Valink Therapeutics. Following his research on protein conjugation technologies at the University of Oxford, he founded Valink Therapeutics as a spin-out of the Department of Biochemistry with the support of the Y Combinator startup accelerator; the company combines his passions for protein engineering and drug discovery. Arne holds a DPhil (PhD) in Biochemistry from the University of Oxford, has been awarded the Rhodes Scholarship for Germany, and has been listed as Forbes 30 Under 30 Europe 2024.
Seminars
Wednesday 18th March 2026
Beyond Binary: Unlocking the Potential of Bispecific ADCs
3:30 pm
- Smarter Targeting with V-gate: How logic gating enhances selectivity and safety in bsADC development
- Discovery Innovation: Valink’s unique approach to identifying synergistic target pairs that unlock superior payload delivery and therapeutic windows
- Pipeline Snapshot: A look at Valink’s current development programs and how these breakthroughs are shaping the next generation of conjugate therapies
